Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01555320 : Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
PhaseN/A
AgesMin: 40 Years Max: 79 Years
Eligibility
Inclusion Criteria:

- Age 40 to 79

- Patients with ischemic heart failure?

- LVEF less than or equal to 45% measured by echocardiography in modified Simpson
method

- History of prior myocardial infarction with or without percutaneous coronary
intervention (PCI) or/and coronary artery bypass grafting (CABG);

- Coronary angiography (CAG) or coronary CTA shows more than or equal to 50%
stenosis in at least one of the main coronary arteries with or without
revascularization, of which the researcher thinks that it is closely related to
heart failure;

- With or without dyspnea, fatigue and fluid retention (edema) etc.

- History of heart failure or present with heart failure symptoms for at least 3
months;

- New York Heart Association (NYHA) Class II to IV;

- Submitted informed consent

Exclusion Criteria:

- Acute heart failure or acute exacerbation of chronic heart failure

- Those who have one of the following diseases:

- Acute coronary syndrome within 30 days

- Revascularization therapy within 6 months

- Uncontrolled hypertension with systolic pressure more than or equal to 180mmHg
and/or diastolic pressure more than or equal to 110mmHg

- Second degree type 2 or worse sinoatrial/atrioventricular block without
implantation of pacemaker or uncontrolled malignant cardiac arrhythmia

- Dilated cardiomyopathy

- Hypertrophic obstructive cardiomyopathy

- Myocarditis

- Pulmonary artery embolism

- Severe valvular heart disease

- Pulmonary heart disease

- Stroke within 6 months

- Cardiac resynchronization therapy

- Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days

- Severe endocrine diseases such as hyperthyroidism, etc.

- History of malignant tumor

- Hemoglobin (HB )? 9g/dl

- Alanine aminotransferase (ALT) > 2 times the upper limit of normal

- Serum creatinine > 265 ?mol/L

- Mental disorder

- Being pregnant, planning for pregnancy or breastfeeding

- Suspicious or definite allergy to intervention drugs

- Participated in other trials within 2 months

- Unable to walk autonomously due to physical disabilities
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01555320      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740